Mirum Pharmaceuticals Valuation
| MIRM Stock | USD 46.65 1.50 3.32% |
At this time, the firm appears to be undervalued. Mirum Pharmaceuticals secures a last-minute Real Value of $49.01 per share. The latest price of the firm is $46.65. Our model forecasts the value of Mirum Pharmaceuticals from analyzing the firm fundamentals such as Current Valuation of 2.27 B, profit margin of (0.33) %, and Return On Equity of -0.4 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Mirum Pharmaceuticals' valuation include:
Price Book 9.6516 | Enterprise Value 2.3 B | Enterprise Value Ebitda (8.85) | Price Sales 7.2938 | Forward PE 67.5676 |
Undervalued
Today
Please note that Mirum Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Mirum Pharmaceuticals is based on 3 months time horizon. Increasing Mirum Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Mirum stock is determined by what a typical buyer is willing to pay for full or partial control of Mirum Pharmaceuticals. Since Mirum Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mirum Stock. However, Mirum Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 46.65 | Real 49.01 | Target 55.43 | Hype 46.27 |
The intrinsic value of Mirum Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mirum Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mirum Pharmaceuticals helps investors to forecast how Mirum stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mirum Pharmaceuticals more accurately as focusing exclusively on Mirum Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Mirum Pharmaceuticals' intrinsic value based on its ongoing forecasts of Mirum Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Mirum Pharmaceuticals' closest peers.
Mirum Pharmaceuticals Cash |
|
Mirum Valuation Trend
Knowing Mirum Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Mirum Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Mirum Revenue by Product
Mirum Pharmaceuticals Total Value Analysis
Mirum Pharmaceuticals is now projected to have valuation of 2.27 B with market capitalization of 2.24 B, debt of 308.14 M, and cash on hands of 124.95 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Mirum Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.27 B | 2.24 B | 308.14 M | 124.95 M |
Mirum Pharmaceuticals Investor Information
About 98.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 2.08. Mirum Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Mirum Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Mirum Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Mirum Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Mirum Pharmaceuticals has an asset utilization ratio of 28.82 percent. This suggests that the Company is making $0.29 for each dollar of assets. An increasing asset utilization means that Mirum Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Mirum Pharmaceuticals Ownership Allocation
The majority of Mirum Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Mirum Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Mirum Pharmaceuticals. Please pay attention to any change in the institutional holdings of Mirum Pharmaceuticals as this could imply that something significant has changed or is about to change at the company.Mirum Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 186.37 M. Net Loss for the year was (163.41 M) with profit before overhead, payroll, taxes, and interest of 64.69 M.About Mirum Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Mirum Pharmaceuticals. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Mirum Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Mirum Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Mirum Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Mirum Pharmaceuticals. We calculate exposure to Mirum Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Mirum Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 139.3 M | 146.3 M | |
| Pretax Profit Margin | (0.87) | (0.92) | |
| Operating Profit Margin | (0.59) | (0.61) | |
| Net Loss | (0.88) | (0.92) | |
| Gross Profit Margin | 0.75 | 0.91 |
Mirum Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Mirum Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 40.9 M | |
| Forward Price Earnings | 67.5676 |
Mirum Pharmaceuticals Current Valuation Indicators
Mirum Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Mirum Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Mirum Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Mirum Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Mirum Pharmaceuticals' worth.When determining whether Mirum Pharmaceuticals is a strong investment it is important to analyze Mirum Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Mirum Pharmaceuticals' future performance. For an informed investment choice regarding Mirum Stock, refer to the following important reports: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mirum Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Mirum Stock, please use our How to Invest in Mirum Pharmaceuticals guide.You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mirum Pharmaceuticals. If investors know Mirum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mirum Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 6.513 | Quarterly Revenue Growth 0.894 | Return On Assets (0.09) | Return On Equity (0.40) |
The market value of Mirum Pharmaceuticals is measured differently than its book value, which is the value of Mirum that is recorded on the company's balance sheet. Investors also form their own opinion of Mirum Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Mirum Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mirum Pharmaceuticals' market value can be influenced by many factors that don't directly affect Mirum Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mirum Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mirum Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mirum Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.